1. Home
  2. CMPX vs ALT Comparison

CMPX vs ALT Comparison

Compare CMPX & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CMPX
  • ALT
  • Stock Information
  • Founded
  • CMPX 2014
  • ALT 1997
  • Country
  • CMPX United States
  • ALT United States
  • Employees
  • CMPX N/A
  • ALT N/A
  • Industry
  • CMPX Biotechnology: Pharmaceutical Preparations
  • ALT Biotechnology: Pharmaceutical Preparations
  • Sector
  • CMPX Health Care
  • ALT Health Care
  • Exchange
  • CMPX Nasdaq
  • ALT Nasdaq
  • Market Cap
  • CMPX 291.8M
  • ALT 339.0M
  • IPO Year
  • CMPX N/A
  • ALT N/A
  • Fundamental
  • Price
  • CMPX $3.20
  • ALT $4.03
  • Analyst Decision
  • CMPX Strong Buy
  • ALT Strong Buy
  • Analyst Count
  • CMPX 9
  • ALT 6
  • Target Price
  • CMPX $12.67
  • ALT $18.20
  • AVG Volume (30 Days)
  • CMPX 729.4K
  • ALT 5.7M
  • Earning Date
  • CMPX 08-11-2025
  • ALT 08-07-2025
  • Dividend Yield
  • CMPX N/A
  • ALT N/A
  • EPS Growth
  • CMPX N/A
  • ALT N/A
  • EPS
  • CMPX N/A
  • ALT N/A
  • Revenue
  • CMPX $850,000.00
  • ALT $20,000.00
  • Revenue This Year
  • CMPX N/A
  • ALT N/A
  • Revenue Next Year
  • CMPX N/A
  • ALT $507,435.66
  • P/E Ratio
  • CMPX N/A
  • ALT N/A
  • Revenue Growth
  • CMPX N/A
  • ALT N/A
  • 52 Week Low
  • CMPX $0.87
  • ALT $2.90
  • 52 Week High
  • CMPX $4.08
  • ALT $11.16
  • Technical
  • Relative Strength Index (RSI)
  • CMPX 64.53
  • ALT 39.54
  • Support Level
  • CMPX $3.11
  • ALT $4.01
  • Resistance Level
  • CMPX $3.45
  • ALT $4.39
  • Average True Range (ATR)
  • CMPX 0.20
  • ALT 0.22
  • MACD
  • CMPX 0.01
  • ALT 0.03
  • Stochastic Oscillator
  • CMPX 69.33
  • ALT 12.67

About CMPX Compass Therapeutics Inc.

Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: